Jonathan Harvey Soslow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathan Harvey Soslow has a total of 461 co-authors. Here are the top co-authors by number of shared publications:
- Kristen George-Durrett
Vanderbilt University Medical Center, Nashville, TN, USA
11 shared publications Meng Xu
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
10 shared publicationsKimberly Crum
Department of Pediatrics, Vanderbilt University Medical Center
9 shared publications- Larry W. Markham
Vanderbilt University Medical Center, Nashville, TN, USA
9 shared publications - James Christopher Slaughter
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
8 shared publications David A. Parra
Thomas P. Graham Jr. Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, USA
7 shared publications
Latest Publications
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Body Mass Index, Valsartan, and Myocardial Remodeling in Early‐Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial
Background: Obesity is associated with adverse outcomes in overt hypertrophic cardiomyopathy, but the prevalence and impact of elevated body mass index (BMI) in early‐stage hypertrophic cardiomyopathy is uncertain. Methods: In this post hoc analysis of the randomized VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) trial, participants were categorized according to baseline BMI (nonelevated or elevated [≥85th percentile if age 2 if age ≥18 years]). Exercise capacity (peak oxygen uptake [milliliters per kilogram per minute]) and cardiac imaging parameters were evaluated by baseline BMI and 2‐year change in BMI. Results: Among 171 (96%) participants (mean age, 23±10 years; 39% female sex; 97% White), 82 (48%) had nonelevated BMI and 89 (52%) had an elevated BMI. After covariate adjustment, higher baseline BMI was associated with lower peak oxygen uptake; lower left ventricular systolic and diastolic function; higher left ventricular mass; and higher atrial, ventricular, and extracellular volumes. Similarly, greater 2‐year increases in BMI were associated with greater declines in peak oxygen uptake and greater increases in left ventricular mass. Participants with elevated BMI were more likely to develop late gadolinium enhancement over 2 years (adjusted odds ratio, 3.6 [95% CI, 1.1–11.9]; P =0.033). Valsartan appeared to modestly attenuate 2‐year increases in body weight versus placebo (adjusted mean difference, −3.1% [95% CI, −6.2 to −0.1%]; P =0.042). Baseline BMI did not appear to modify the effect of valsartan on cardiac remodeling ( P interaction =0.96). Conclusions: Elevated BMI was common and associated with greater hypertrophic, eccentric, and fibrotic remodeling in early‐stage hypertrophic cardiomyopathy. Two‐year increases in BMI were associated with greater phenotypic progression. These findings suggest prevention and treatment of elevated BMI may attenuate hypertrophic cardiomyopathy progression. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01912534.
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Body Mass Index, Valsartan, and Myocardial Remodeling in Early‐Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial
Background: Obesity is associated with adverse outcomes in overt hypertrophic cardiomyopathy, but the prevalence and impact of elevated body mass index (BMI) in early‐stage hypertrophic cardiomyopathy is uncertain. Methods: In this post hoc analysis of the randomized VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) trial, participants were categorized according to baseline BMI (nonelevated or elevated [≥85th percentile if age 2 if age ≥18 years]). Exercise capacity (peak oxygen uptake [milliliters per kilogram per minute]) and cardiac imaging parameters were evaluated by baseline BMI and 2‐year change in BMI. Results: Among 171 (96%) participants (mean age, 23±10 years; 39% female sex; 97% White), 82 (48%) had nonelevated BMI and 89 (52%) had an elevated BMI. After covariate adjustment, higher baseline BMI was associated with lower peak oxygen uptake; lower left ventricular systolic and diastolic function; higher left ventricular mass; and higher atrial, ventricular, and extracellular volumes. Similarly, greater 2‐year increases in BMI were associated with greater declines in peak oxygen uptake and greater increases in left ventricular mass. Participants with elevated BMI were more likely to develop late gadolinium enhancement over 2 years (adjusted odds ratio, 3.6 [95% CI, 1.1–11.9]; P =0.033). Valsartan appeared to modestly attenuate 2‐year increases in body weight versus placebo (adjusted mean difference, −3.1% [95% CI, −6.2 to −0.1%]; P =0.042). Baseline BMI did not appear to modify the effect of valsartan on cardiac remodeling ( P interaction =0.96). Conclusions: Elevated BMI was common and associated with greater hypertrophic, eccentric, and fibrotic remodeling in early‐stage hypertrophic cardiomyopathy. Two‐year increases in BMI were associated with greater phenotypic progression. These findings suggest prevention and treatment of elevated BMI may attenuate hypertrophic cardiomyopathy progression. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01912534.
- 28 August 2026
- Published by Wolters Kluwer Health in Circulation
Low Ventricular Chamber Stiffness Identifies a High-Risk Eccentric Remodeling Phenotype in the Fontan Circulation: A FORCE Registry Analysis
BACKGROUND: Rising end-diastolic pressure in patients with a Fontan circulation has led to the hypothesis that circulatory failure is driven by progressive ventricular stiffening. However, end-diastolic pressure is influenced by loading conditions and extracardiac constraint and may not accurately reflect chamber stiffness. We aimed to characterize ventricular chamber stiffness using the end-diastolic pressure-volume relationship and examine its clinical and prognostic significance in patients with a Fontan circulation. METHODS: In the FORCE registry (Fontan Outcomes Registry Using Clinical Examinations), chamber stiffness was quantified with the exponential coefficient β derived from single-beat end-diastolic pressure-volume relationship reconstruction using paired catheterization and cardiovascular magnetic resonance data. The β values were standardized as body surface area– and sex-based Z scores and related to clinical characteristics, ventricular remodeling, and a composite adverse outcome (death, transplantation listing, sustained atrial or ventricular arrhythmias, protein-losing enteropathy, or plastic bronchitis). RESULTS: Among 814 patients (median age, 14.7 years), median β was 0.034 mL −1 (0.025–0.046). Lower β Z score was associated with dominant right ventricle, eccentric remodeling with reduced ejection fraction, increased collateral flow and intracardiac recirculation, greater symptom burden, and higher arrhythmia prevalence, despite similar filling pressures. Over a median follow-up of 2.7 years (0.9–6.1 years), lower β Z score independently predicted adverse outcomes (adjusted hazard ratio, 1.30 per 1-SD decrease [95% CI 1.04–1.61]). A β Z score <−0.71, β103 mL/m 2 showed similarly modest discrimination for adverse outcomes overall (area under the curve, 0.59), with greater discrimination in dominant right ventricles. CONCLUSIONS: Contrary to prevailing assumptions, lower rather than higher chamber stiffness was associated with adverse Fontan outcomes, identifying a high-compliance phenotype characterized by ventricular dilation and eccentric remodeling. These findings suggest that, in the contemporary FORCE cohort, Fontan failure might be more closely associated with this remodeling phenotype than with progressive stiffening.
- 28 August 2026
- Published by Wolters Kluwer Health in Circulation
Low Ventricular Chamber Stiffness Identifies a High-Risk Eccentric Remodeling Phenotype in the Fontan Circulation: A FORCE Registry Analysis
BACKGROUND: Rising end-diastolic pressure in patients with a Fontan circulation has led to the hypothesis that circulatory failure is driven by progressive ventricular stiffening. However, end-diastolic pressure is influenced by loading conditions and extracardiac constraint and may not accurately reflect chamber stiffness. We aimed to characterize ventricular chamber stiffness using the end-diastolic pressure-volume relationship and examine its clinical and prognostic significance in patients with a Fontan circulation. METHODS: In the FORCE registry (Fontan Outcomes Registry Using Clinical Examinations), chamber stiffness was quantified with the exponential coefficient β derived from single-beat end-diastolic pressure-volume relationship reconstruction using paired catheterization and cardiovascular magnetic resonance data. The β values were standardized as body surface area– and sex-based Z scores and related to clinical characteristics, ventricular remodeling, and a composite adverse outcome (death, transplantation listing, sustained atrial or ventricular arrhythmias, protein-losing enteropathy, or plastic bronchitis). RESULTS: Among 814 patients (median age, 14.7 years), median β was 0.034 mL −1 (0.025–0.046). Lower β Z score was associated with dominant right ventricle, eccentric remodeling with reduced ejection fraction, increased collateral flow and intracardiac recirculation, greater symptom burden, and higher arrhythmia prevalence, despite similar filling pressures. Over a median follow-up of 2.7 years (0.9–6.1 years), lower β Z score independently predicted adverse outcomes (adjusted hazard ratio, 1.30 per 1-SD decrease [95% CI 1.04–1.61]). A β Z score <−0.71, β103 mL/m 2 showed similarly modest discrimination for adverse outcomes overall (area under the curve, 0.59), with greater discrimination in dominant right ventricles. CONCLUSIONS: Contrary to prevailing assumptions, lower rather than higher chamber stiffness was associated with adverse Fontan outcomes, identifying a high-compliance phenotype characterized by ventricular dilation and eccentric remodeling. These findings suggest that, in the contemporary FORCE cohort, Fontan failure might be more closely associated with this remodeling phenotype than with progressive stiffening.
- Open Access
- 5 August 2026
- Published by SAGE Publications in Human Gene Therapy
- Vol. 37 (23-24) , 1158-1166
Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy
Delandistrogene moxeparvovec-rokl (DMR) is the only U.S. Food and Drug Administration-approved gene therapy for patients with Duchenne muscular dystrophy (DMD). After reports of two deaths due to acute liver injury (ALI)/acute liver failure, our center began prophylaxis with sirolimus to help prevent ALI. The objective of this study is to report the initial safety, tolerability, and efficacy of sirolimus prophylaxis. The clinical course of patients receiving sirolimus prophylaxis with a target trough of 4–6 ng/mL was retrospectively evaluated and compared with those who did not receive sirolimus. Laboratory testing, particularly gamma glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, and total bilirubin, was collected. A Fisher’s exact test was used to assess the difference between groups. Twelve patients were started on sirolimus prophylaxis, 10 prior to DMR infusion and 2 within 2 weeks of DMR. The median age at DMR dosing was 11 years old (interquartile range = 8.5–14); 11 patients were ambulatory. No patients experienced a serious adverse event related to sirolimus administration. Seven patients developed elevated triglyceride or cholesterol levels and began omega-3 supplementation. None of the patients receiving sirolimus prophylaxis experienced ALI compared with 3 of the 14 patients (21%) infused prior to implementation of the sirolimus protocol. Sirolimus prophylaxis appears to be safe and well-tolerated in DMD patients receiving DMR. While not statistically significant, these results suggest that further study of sirolimus prophylaxis is warranted.
- 5 August 2026
- Published by SAGE Publications in Human Gene Therapy
- Vol. 37 (23-24) , 1158-1166
Open AccessSafety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy
Delandistrogene moxeparvovec-rokl (DMR) is the only U.S. Food and Drug Administration-approved gene therapy for patients with Duchenne muscular dystrophy (DMD). After reports of two deaths due to acute liver injury (ALI)/acute liver failure, our center began prophylaxis with sirolimus to help prevent ALI. The objective of this study is to report the initial safety, tolerability, and efficacy of sirolimus prophylaxis. The clinical course of patients receiving sirolimus prophylaxis with a target trough of 4–6 ng/mL was retrospectively evaluated and compared with those who did not receive sirolimus. Laboratory testing, particularly gamma glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, and total bilirubin, was collected. A Fisher’s exact test was used to assess the difference between groups. Twelve patients were started on sirolimus prophylaxis, 10 prior to DMR infusion and 2 within 2 weeks of DMR. The median age at DMR dosing was 11 years old (interquartile range = 8.5–14); 11 patients were ambulatory. No patients experienced a serious adverse event related to sirolimus administration. Seven patients developed elevated triglyceride or cholesterol levels and began omega-3 supplementation. None of the patients receiving sirolimus prophylaxis experienced ALI compared with 3 of the 14 patients (21%) infused prior to implementation of the sirolimus protocol. Sirolimus prophylaxis appears to be safe and well-tolerated in DMD patients receiving DMR. While not statistically significant, these results suggest that further study of sirolimus prophylaxis is warranted.
- Open Access
- 1 July 2026
- Published by Springer Nature in Cardiology and Therapy
- Vol. 15 (3) , 1-17
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up
Introduction In patients with Duchenne muscular dystrophy (DMD), the gene transfer therapy delandistrogene moxeparvovec delivers a functional form of dystrophin, which has been shown to stabilize or slow disease progression. Methods We assessed cardiac safety of delandistrogene moxeparvovec in clinical trials with ≤ 5 years of follow-up. Data were collected from clinical trials 101 (NCT03375164, n = 4), 102 (NCT03769116, n = 41), ENDEAVOR (NCT04626674, n = 48), and EMBARK (NCT05096221, n = 125), which excluded patients with left ventricular ejection fraction (LVEF) < 40%. Adverse events and cardiac echocardiography were assessed regularly in all trials. Troponin I was assessed regularly in ENDEAVOR and EMBARK. Cardiac magnetic resonance imaging (MRI; without gadolinium enhancement) was assessed within an EMBARK substudy. Results Of 218 patients (baseline mean age [range], 6.4 [3.2–20.2] years; mean LVEF [range], 63.8% [48.9–78.0%]), 210 (96%) were ambulatory; 216 received delandistrogene moxeparvovec treatment. Two myocarditis cases were reported within 4 days after delandistrogene moxeparvovec infusion; both resolved within 3 weeks. Except in the two myocarditis cases, troponin I fluctuations were asymptomatic. Thirteen patients with baseline and postbaseline echocardiography data had elevated troponin I at baseline; 1 year post infusion, only one of these patients had LVEF < 50%. LVEF in all four patients with 5-year follow-up remained > 50%. Although cardiac MRI without gadolinium revealed no relevant differences in heart function between patients 1 or 2 years after delandistrogene moxeparvovec versus patients 1 year after placebo infusion, subclinical fibrosis cannot be ruled out. Conclusion Results from delandistrogene moxeparvovec trials with 1 to 5 years of follow-up suggest a manageable cardiac safety profile in this study population of predominantly younger, ambulatory patients with DMD who had no signs of persistent treatment-related cardiac injury.
- 1 July 2026
- Published by Springer Nature in Cardiology and Therapy
- Vol. 15 (3) , 1-17
Open AccessCardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up
Introduction In patients with Duchenne muscular dystrophy (DMD), the gene transfer therapy delandistrogene moxeparvovec delivers a functional form of dystrophin, which has been shown to stabilize or slow disease progression. Methods We assessed cardiac safety of delandistrogene moxeparvovec in clinical trials with ≤ 5 years of follow-up. Data were collected from clinical trials 101 (NCT03375164, n = 4), 102 (NCT03769116, n = 41), ENDEAVOR (NCT04626674, n = 48), and EMBARK (NCT05096221, n = 125), which excluded patients with left ventricular ejection fraction (LVEF) < 40%. Adverse events and cardiac echocardiography were assessed regularly in all trials. Troponin I was assessed regularly in ENDEAVOR and EMBARK. Cardiac magnetic resonance imaging (MRI; without gadolinium enhancement) was assessed within an EMBARK substudy. Results Of 218 patients (baseline mean age [range], 6.4 [3.2–20.2] years; mean LVEF [range], 63.8% [48.9–78.0%]), 210 (96%) were ambulatory; 216 received delandistrogene moxeparvovec treatment. Two myocarditis cases were reported within 4 days after delandistrogene moxeparvovec infusion; both resolved within 3 weeks. Except in the two myocarditis cases, troponin I fluctuations were asymptomatic. Thirteen patients with baseline and postbaseline echocardiography data had elevated troponin I at baseline; 1 year post infusion, only one of these patients had LVEF < 50%. LVEF in all four patients with 5-year follow-up remained > 50%. Although cardiac MRI without gadolinium revealed no relevant differences in heart function between patients 1 or 2 years after delandistrogene moxeparvovec versus patients 1 year after placebo infusion, subclinical fibrosis cannot be ruled out. Conclusion Results from delandistrogene moxeparvovec trials with 1 to 5 years of follow-up suggest a manageable cardiac safety profile in this study population of predominantly younger, ambulatory patients with DMD who had no signs of persistent treatment-related cardiac injury.
- Open Access
- 8 June 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (6) , 1208-1214
Assessment of improvements in exercise tolerance following pulmonary valve replacement using physical accelerometry
Background: Pulmonary valve replacement may be required for patients with pulmonary valve disease. Exertional symptoms related to cardiovascular disease are an indication for pulmonary valve replacement; however, quantification of symptom improvement postoperatively is challenging, and previous studies have yielded mixed data. Accelerometry has the potential to remotely monitor changes in exercise tolerance following pulmonary valve replacement. Methods: Individuals ( n = 18) age >13 years scheduled for catheter-based or surgical pulmonary valve replacement were prospectively enrolled. Participants were instructed to wear two Link GT9X accelerometers, placed on dominant wrist and one ankle, for seven days and nights before pulmonary valve replacement and again 3–6 months after the procedure. Results: The cohort’s median age was 26.5 [16.0, 35.0] years old. Compliance of both wrist and ankle accelerometers had a median of 96% or greater at both timepoints suggesting adequate participation. Accelerometry showed stability between participants. Quantitative analysis using pre-and post-pulmonary valve replacement accelerometer-derived measures yielded no significant differences. There was a significant decrease in the average score for items “Shortness of Breath with Strenuous Activity,” “Extent Symptoms Impact Daily Activities,” and “Challenges with Activities of Daily Living.” Furthermore, all 9 individuals with baseline exertional intolerance had resolution of symptom in postoperative assessment. Conclusion: Reliability of accelerometer-derived activity measurements supports usage of physical accelerometry as a remote outcome measure to reduce patient burden for onsite assessment. Mixed qualitative versus quantitative improvement in physical activity tolerance observed in this study aligns with previous studies on variable improvement in exercise tolerance following pulmonary valve replacement. This discrepancy suggests the need for a different quantitative mechanism to measure benefit.
- 8 June 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (6) , 1208-1214
Open AccessAssessment of improvements in exercise tolerance following pulmonary valve replacement using physical accelerometry
Background: Pulmonary valve replacement may be required for patients with pulmonary valve disease. Exertional symptoms related to cardiovascular disease are an indication for pulmonary valve replacement; however, quantification of symptom improvement postoperatively is challenging, and previous studies have yielded mixed data. Accelerometry has the potential to remotely monitor changes in exercise tolerance following pulmonary valve replacement. Methods: Individuals ( n = 18) age >13 years scheduled for catheter-based or surgical pulmonary valve replacement were prospectively enrolled. Participants were instructed to wear two Link GT9X accelerometers, placed on dominant wrist and one ankle, for seven days and nights before pulmonary valve replacement and again 3–6 months after the procedure. Results: The cohort’s median age was 26.5 [16.0, 35.0] years old. Compliance of both wrist and ankle accelerometers had a median of 96% or greater at both timepoints suggesting adequate participation. Accelerometry showed stability between participants. Quantitative analysis using pre-and post-pulmonary valve replacement accelerometer-derived measures yielded no significant differences. There was a significant decrease in the average score for items “Shortness of Breath with Strenuous Activity,” “Extent Symptoms Impact Daily Activities,” and “Challenges with Activities of Daily Living.” Furthermore, all 9 individuals with baseline exertional intolerance had resolution of symptom in postoperative assessment. Conclusion: Reliability of accelerometer-derived activity measurements supports usage of physical accelerometry as a remote outcome measure to reduce patient burden for onsite assessment. Mixed qualitative versus quantitative improvement in physical activity tolerance observed in this study aligns with previous studies on variable improvement in exercise tolerance following pulmonary valve replacement. This discrepancy suggests the need for a different quantitative mechanism to measure benefit.
- Open Access
- 3 April 2026
- Published by Elsevier in SSRN Electronic Journal
Deramiocel Heart-Derived Cellular Therapy in Advanced Duchenne Muscular Dystrophy (HOPE-3): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial
Background: Deramiocel, a heart-derived cellular therapy, improved cardiac and skeletal muscle function in phase 1-2 studies of Duchenne muscular dystrophy (DMD). This phase 3 study was conducted to confirm the efficacy and safety of deramiocel in advanced DMD.Methods: HOPE (Halt cardiOmyopathy ProgrEssion)-3, a multicenter, randomised (1:1 ratio), double-blind placebo-controlled study, included 106 participants with DMD aged ≥10 years. Investigational product was infused intravenously every 3 months in outpatient settings. Skeletal and cardiac muscle function, measured by the total and mid-level Performance of the Upper Limb 2.0 (PUL2.0), and cardiac magnetic resonance (CMR) imaging outcomes, including left ventricular ejection fraction (LVEF) and late gadolinium enhancement (LGE), were evaluated at 12 months. A global statistical test (GST) combined total PUL2.0, CMR LVEF, and patient global impression of severity.Findings: The primary and all Type-1-error controlled secondary efficacy endpoints demonstrated significant improvements in the deramiocel group versus placebo. For PUL2.0, mean percent change at 12 months favoured deramiocel by 4.55% for Total (95% CI 0.47 - 8.63; p=0.029) and 8.12% for Mid-level (95% CI 2.12 - 14.11; p=0.008). For LVEF, ranked change from baseline favoured deramiocel by 11.65 (95% CI 0.47 - 22.82; p=0.041). The absolute mean change in LVEF(%) showed a treatment benefit of 2.4-percentage points. For LGE, a measure of cardiac scarring, the mean change from baseline in number of affected segments favoured deramiocel by -3.00 (95% CI -5.50 - 0.51; p=0.022). The GST favoured deramiocel with z-score of 0.27 (95% CI 0.05 - 0.49; p=0.015). Deramiocel had a safety profile comparable to that of placebo.Interpretation: Deramiocel safely slows disease progression in advanced DMD, preserving both skeletal and cardiac muscle function. Administered quarterly in a simple outpatient regimen, deramiocel is a promising treatment for skeletal and cardiac disease in DMD, agnostic to the precise underlying genetic lesion.
- 3 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDeramiocel Heart-Derived Cellular Therapy in Advanced Duchenne Muscular Dystrophy (HOPE-3): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial
Background: Deramiocel, a heart-derived cellular therapy, improved cardiac and skeletal muscle function in phase 1-2 studies of Duchenne muscular dystrophy (DMD). This phase 3 study was conducted to confirm the efficacy and safety of deramiocel in advanced DMD.Methods: HOPE (Halt cardiOmyopathy ProgrEssion)-3, a multicenter, randomised (1:1 ratio), double-blind placebo-controlled study, included 106 participants with DMD aged ≥10 years. Investigational product was infused intravenously every 3 months in outpatient settings. Skeletal and cardiac muscle function, measured by the total and mid-level Performance of the Upper Limb 2.0 (PUL2.0), and cardiac magnetic resonance (CMR) imaging outcomes, including left ventricular ejection fraction (LVEF) and late gadolinium enhancement (LGE), were evaluated at 12 months. A global statistical test (GST) combined total PUL2.0, CMR LVEF, and patient global impression of severity.Findings: The primary and all Type-1-error controlled secondary efficacy endpoints demonstrated significant improvements in the deramiocel group versus placebo. For PUL2.0, mean percent change at 12 months favoured deramiocel by 4.55% for Total (95% CI 0.47 - 8.63; p=0.029) and 8.12% for Mid-level (95% CI 2.12 - 14.11; p=0.008). For LVEF, ranked change from baseline favoured deramiocel by 11.65 (95% CI 0.47 - 22.82; p=0.041). The absolute mean change in LVEF(%) showed a treatment benefit of 2.4-percentage points. For LGE, a measure of cardiac scarring, the mean change from baseline in number of affected segments favoured deramiocel by -3.00 (95% CI -5.50 - 0.51; p=0.022). The GST favoured deramiocel with z-score of 0.27 (95% CI 0.05 - 0.49; p=0.015). Deramiocel had a safety profile comparable to that of placebo.Interpretation: Deramiocel safely slows disease progression in advanced DMD, preserving both skeletal and cardiac muscle function. Administered quarterly in a simple outpatient regimen, deramiocel is a promising treatment for skeletal and cardiac disease in DMD, agnostic to the precise underlying genetic lesion.
- Top Cited PapersOpen Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e044160
Multimodal Cardiac Imaging of Immune‐Mediated Complications Post Heart Transplantation: A Contemporary Review
Heart transplantation significantly enhances survival and quality of life for patients with end‐stage heart failure. Despite advances in surgical and postoperative care, immune‐mediated complications, acute graft rejection and cardiac allograft vasculopathy (CAV), remain major barriers to long‐term success. Acute rejection predominantly affects early posttransplant survival, whereas CAV becomes a leading cause of mortality in later years. The gold standards for diagnosis, endomyocardial biopsy for rejection and coronary angiography for CAV, are invasive and imperfect. Noninvasive multimodality imaging is increasingly used to complement or, in selected scenarios, defer invasive testing. Echocardiography with strain detects early myocardial dysfunction when ejection fraction is preserved; stress echocardiography provides prognostic information for CAV. Quantitative techniques, positron emission tomography myocardial blood flow/myocardial flow reserve and quantitative cardiac magnetic resonance perfusion, improve detection of diffuse, stage‐dependent CAV compared with qualitative assessments. Cardiac magnetic resonance tissue mapping characterizes edema and fibrosis relevant to rejection surveillance; fluorodeoxyglucose‐positron emission tomography for inflammation is emerging but remains investigational in most centers. Cardiac computed tomography angiography defines coronary anatomy and plaque with excellent negative predictive value and offers physiologic assessment with computed tomography‐myocardial perfusion imaging/computed tomography‐derived fractional flow reserve; it is best used strategically rather than as an annually repeated test. This contemporary review synthesizes the strengths, limitations, and practical roles of echocardiography, nuclear imaging, cardiac magnetic resonance, and cardiac computed tomography angiography across adult and pediatric populations; highlights areas where quantitative methods add incremental value; and provides pragmatic, stage‐aware surveillance frameworks. Integrating modalities can reduce reliance on invasive procedures, lower procedural risk, and refine therapeutic decision‐making benefits that are particularly relevant for children and other patients for whom repeated invasive testing is undesirable.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e044160
Top Cited PapersOpen AccessMultimodal Cardiac Imaging of Immune‐Mediated Complications Post Heart Transplantation: A Contemporary Review
Heart transplantation significantly enhances survival and quality of life for patients with end‐stage heart failure. Despite advances in surgical and postoperative care, immune‐mediated complications, acute graft rejection and cardiac allograft vasculopathy (CAV), remain major barriers to long‐term success. Acute rejection predominantly affects early posttransplant survival, whereas CAV becomes a leading cause of mortality in later years. The gold standards for diagnosis, endomyocardial biopsy for rejection and coronary angiography for CAV, are invasive and imperfect. Noninvasive multimodality imaging is increasingly used to complement or, in selected scenarios, defer invasive testing. Echocardiography with strain detects early myocardial dysfunction when ejection fraction is preserved; stress echocardiography provides prognostic information for CAV. Quantitative techniques, positron emission tomography myocardial blood flow/myocardial flow reserve and quantitative cardiac magnetic resonance perfusion, improve detection of diffuse, stage‐dependent CAV compared with qualitative assessments. Cardiac magnetic resonance tissue mapping characterizes edema and fibrosis relevant to rejection surveillance; fluorodeoxyglucose‐positron emission tomography for inflammation is emerging but remains investigational in most centers. Cardiac computed tomography angiography defines coronary anatomy and plaque with excellent negative predictive value and offers physiologic assessment with computed tomography‐myocardial perfusion imaging/computed tomography‐derived fractional flow reserve; it is best used strategically rather than as an annually repeated test. This contemporary review synthesizes the strengths, limitations, and practical roles of echocardiography, nuclear imaging, cardiac magnetic resonance, and cardiac computed tomography angiography across adult and pediatric populations; highlights areas where quantitative methods add incremental value; and provides pragmatic, stage‐aware surveillance frameworks. Integrating modalities can reduce reliance on invasive procedures, lower procedural risk, and refine therapeutic decision‐making benefits that are particularly relevant for children and other patients for whom repeated invasive testing is undesirable.
- Open Access
- 1 January 2026
- Published by BMJ in Open Heart
- Vol. 13 (1) , e004037
Cardiac MRI in cardiac dystrophinopathy: recommendations on imaging
Heart pumping weakness occurs progressively in all patients with Duchenne muscular dystrophy (DMD), but symptoms only occur very late in the process. Regular imaging assessments of heart function are needed to see how the heart is ‘doing’ and how well it is responding to treatment with heart drugs. Echocardiography (echo) has been the standard type of imaging used for these assessments in the UK. It is widely available but has limitations. Cardiac MRI (CMR), although less readily available and more expensive, is better able to detect tissue changes in the heart before there is any reduction of heart pump function and retains accuracy in all measures even as DMD progresses. An expert panel of cardiologists, muscle specialists and patient representatives was set up to review evidence and provide expert guidance on how to use both echo and CMR best to the benefit of patients with DMD, Becker muscular dystrophy (BMD) and females affected by DMD-gene abnormalities (‘female gene carriers’). The working group concluded that echo should remain the predominant method used in heart checks for patients with DMD in the UK. However, wider use of CMR, performed at times individualised to key decision points after about the age of 10 years, would allow earlier detection of those heart changes prompting the introduction and changes in heart therapies. Similarly, greater use of CMR could contribute to improving cardiac management of males with BMD and females with DMD-gene variations. _______________________ Objective: To provide guidance on the use of cardiac MRI (CMR) in the UK in paediatric and adult patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) as well as recommendations for screening and monitoring females with dystrophin-gene variations. Specifically, to examine the ‘added value’ of CMR over echocardiography at selected time points in the assessment of individuals with or at risk of developing cardiac dystrophinopathy. Methods: Initiated by an expert working group of UK-based and US-based imaging cardiologists, neuromuscular clinicians and DMD-patient representatives, draft guidelines were created based on published evidence, current practice and expert opinion. After wider consultation with UK cardiologists, consensus was reached on the optimal use of CMR in clinical decision-making about therapy. Results and conclusions: Echocardiography should remain the predominant modality for cardiac surveillance and to guide therapy for patients with DMD in the UK. However, when tolerated, wider use of CMR at key stages in patients with DMD, older than age 10 years, and for males with BMD and females with DMD-gene variations would allow earlier detection of those with cardiac involvement and inform the earlier initiation of regimes of cardiac medications. In this way, greater use of CMR could contribute to improving cardiac health in each of these patient groups.
- 1 January 2026
- Published by BMJ in Open Heart
- Vol. 13 (1) , e004037
Open AccessCardiac MRI in cardiac dystrophinopathy: recommendations on imaging
Heart pumping weakness occurs progressively in all patients with Duchenne muscular dystrophy (DMD), but symptoms only occur very late in the process. Regular imaging assessments of heart function are needed to see how the heart is ‘doing’ and how well it is responding to treatment with heart drugs. Echocardiography (echo) has been the standard type of imaging used for these assessments in the UK. It is widely available but has limitations. Cardiac MRI (CMR), although less readily available and more expensive, is better able to detect tissue changes in the heart before there is any reduction of heart pump function and retains accuracy in all measures even as DMD progresses. An expert panel of cardiologists, muscle specialists and patient representatives was set up to review evidence and provide expert guidance on how to use both echo and CMR best to the benefit of patients with DMD, Becker muscular dystrophy (BMD) and females affected by DMD-gene abnormalities (‘female gene carriers’). The working group concluded that echo should remain the predominant method used in heart checks for patients with DMD in the UK. However, wider use of CMR, performed at times individualised to key decision points after about the age of 10 years, would allow earlier detection of those heart changes prompting the introduction and changes in heart therapies. Similarly, greater use of CMR could contribute to improving cardiac management of males with BMD and females with DMD-gene variations. _______________________ Objective: To provide guidance on the use of cardiac MRI (CMR) in the UK in paediatric and adult patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) as well as recommendations for screening and monitoring females with dystrophin-gene variations. Specifically, to examine the ‘added value’ of CMR over echocardiography at selected time points in the assessment of individuals with or at risk of developing cardiac dystrophinopathy. Methods: Initiated by an expert working group of UK-based and US-based imaging cardiologists, neuromuscular clinicians and DMD-patient representatives, draft guidelines were created based on published evidence, current practice and expert opinion. After wider consultation with UK cardiologists, consensus was reached on the optimal use of CMR in clinical decision-making about therapy. Results and conclusions: Echocardiography should remain the predominant modality for cardiac surveillance and to guide therapy for patients with DMD in the UK. However, when tolerated, wider use of CMR at key stages in patients with DMD, older than age 10 years, and for males with BMD and females with DMD-gene variations would allow earlier detection of those with cardiac involvement and inform the earlier initiation of regimes of cardiac medications. In this way, greater use of CMR could contribute to improving cardiac health in each of these patient groups.
- 21 December 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (1) , e70253
Heart Transplantation and Ventricular Assist Device in Duchenne Muscular Dystrophy: A New Era
Duchenne muscular dystrophy (DMD) is an X‐linked genetic neuromuscular disorder that is caused by a mutation in the dystrophin gene. The disease is characterized by progressive weakness of skeletal muscle, resulting in loss of ambulation and eventually respiratory insufficiency. Cardiac muscle is also involved, and cardiomyopathy is a prominent feature of DMD. The care of patients with DMD has changed in important ways over the past 15 years, with the use of chronic steroid therapy combined with noninvasive respiratory support such as continuous positive airway pressure for home use. More recently, therapies targeting specific genetic mutations in DMD have been approved, using gene‐skipping oligonucleotides, and many other novel therapies are being evaluated in clinical trials, including mini‐dystrophin genes delivered by viral vectors. In view of this new era in care and outcomes, it is appropriate to review the role of advanced cardiac therapies such as ventricular assist devices and heart transplantation in the care of this population. In September 2024, a group of healthcare professionals with expertise in DMD and heart failure convened to review this topic; the consensus opinion of this group (DMD Cardiac Care Consortium) is presented in this manuscript.
- 21 December 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (1) , e70253
Heart Transplantation and Ventricular Assist Device in Duchenne Muscular Dystrophy: A New Era
Duchenne muscular dystrophy (DMD) is an X‐linked genetic neuromuscular disorder that is caused by a mutation in the dystrophin gene. The disease is characterized by progressive weakness of skeletal muscle, resulting in loss of ambulation and eventually respiratory insufficiency. Cardiac muscle is also involved, and cardiomyopathy is a prominent feature of DMD. The care of patients with DMD has changed in important ways over the past 15 years, with the use of chronic steroid therapy combined with noninvasive respiratory support such as continuous positive airway pressure for home use. More recently, therapies targeting specific genetic mutations in DMD have been approved, using gene‐skipping oligonucleotides, and many other novel therapies are being evaluated in clinical trials, including mini‐dystrophin genes delivered by viral vectors. In view of this new era in care and outcomes, it is appropriate to review the role of advanced cardiac therapies such as ventricular assist devices and heart transplantation in the care of this population. In September 2024, a group of healthcare professionals with expertise in DMD and heart failure convened to review this topic; the consensus opinion of this group (DMD Cardiac Care Consortium) is presented in this manuscript.
- Open Access
- 29 November 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 175, 187-195
Six-Minute Activity-95th Centile, a Novel Wearable-Derived Clinical Outcome Assessment for Duchenne Muscular Dystrophy
- 29 November 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 175, 187-195
Open AccessSix-Minute Activity-95th Centile, a Novel Wearable-Derived Clinical Outcome Assessment for Duchenne Muscular Dystrophy